A Research Paper On: Capecitabine as a Targeted Oral Anticancer Agent : Evaluation of Capecitabine(Tablet) and Therapeutic Assessment.

The present research work focused on the detailed study of the oral gastro-retentive dosage forms (GRDFs) of capecitabine, including its drug profile and preformulations studies and comparison of therapeutic potential as a antineoplastic agent with the other antineoplastic agents. Marketed tablet formulations were evaluated based on various physicochemical parameters. Additionally, the therapeutic potential of capecitabine was compared with other anticancer drugs. Capecitabine, a prodrug of 5-fluorouracil (5-FU), has become a cornerstone in the treatment of various solid tumors, particularly colorectal, breast, and gastric cancers. Its unique mechanism of action involves a selective conversion into 5-FU within tumor cells through a series of metabolic steps. This targeted activation helps to minimize systemic toxicity while maximizing anticancer efficacy. Capecitabine has shown substantial effectiveness not only as a single-agent therapy but also in combination regimens, enhancing its versatility in clinical applications. Current research also focuses on identifying predictive biomarkers for better patient selection and exploring novel therapeutic combinations to improve treatment outcomes. These efforts support its potential as a personalized anticancer therapy in the era of precision medicine. In this study, the physicochemical and preformulation studies of capecitabine tablets were carried out, and the prepared formulations were evaluated thoroughly.